Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Xbrane Biopharma, Webcast with teleconference, Q3'24

By Inderes10/24/2024, 11:00 AM
Xbrane Biopharma

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Martin Åmark
00:01 - 12:01

Hello, everybody, and welcome to this webcast in relation to our quarterly report for the third quarter of 2024. Xbrane Biopharma AB, I am Martin Åmark, the CEO, and I have with me Anette Lindqvist, our CFO. In this call. We will, as usual, go through the operational and financial highlights of the quarter. And then we will open up for questions both via audio as well as on the chat. Um, so let's start here. Most of you who are calling in are probably aware of our business model; we are engaged in the development of biosimilars. We have a portfolio that consists of four biosimilars and biosimilar candidates under development. All in all, addressing reference product sales expected to reach about €26 billion by 2026. Our first program, Ximluci, was launched. Similar to the eye drug Lucentis, Ximluci® was approved in Europe and launched there in March 2023 by our partner Stada, and is currently undergoing the regulatory process for approval in the US. Post-approval, it is set to be launched by our US partner, Valarum Biologics. We have, then, two programs: Cimzia® and Opdivo® biosimilar candidates, respectively, that are in a late preclinical stage. We have successfully scaled up the respective production processes and demonstrated comparative analytical similarity to the respective reference products, and we are ready to take the programs into clinical trials during the course of next year. And for these two programs, we're also running very active out-licensing processes with the ambition to identify and tie up a commercialization partner that can also co-fund a significant portion of the continued development of these biosimilar candidates up until they reach the approval stage in Europe and the US. Then we have early stage development of a biosimilar candidate to Darzalex. But we'll start off with Ximluci. This is a snapshot of where we, together with Stada, are from a commercialization perspective, across Europe and the Middle East. We are continuing to see solid volume growth. We had a volume growth of about 23% in Q3 versus Q2 this year, indicating that units were sold to end customers. Despite that, we saw a more or less stable net sales level, which was due to a slightly negative mix effect. This effect essentially reflects the relative volumes coming from different regions with slightly different pricing. And that is most likely going to vary a little bit from quarter to quarter as we continue this journey. But I think the important thing here is that we are continuing to see the strong volume growth trend, and we're very pleased with that. And, Stada is making good progress across a multitude of different countries where the product is launched in Europe. Overall, then, we estimate that Ximluci has a value market share of a little bit above 1% in a market of about €1.2 billion. And that is considering the annual net sales of the originator product, Lucentis, and Lucentis biosimilars on the market in this region. And we're happy to see also that Ximluci is number two from a market share perspective among the different ranibizumab biosimilars in this region. So I think the continued development is going according to plan when it comes to the ongoing commercialization efforts of Ximluci in Europe. We have also started to see approvals in some countries outside of Europe. We've seen approvals in Bahrain, UAE, Uzbekistan, and Switzerland in the recent past. And we are expecting to see launches across these countries in the near term future, along with more approvals and additional countries, particularly in the Middle East region where we have ongoing regulatory processes. Um, and we are working according to the previously communicated plan, to resubmit the BLA to the FDA in the fourth quarter of this year. Um, so for those of you who have followed us, we received a complete response letter on our initial BLA or, that is to say, Biologics License Application to the FDA for Ximluci. We received a complete response letter in April, and we have since then worked through the deficiencies stated by the FDA. Stated in the complete response letter. And that entailed, on the one hand, the qualification of a new reference standard. Since the FDA wanted to see a slightly stricter band for one specific analytical method on the reference standard to be used for releasing the product in the US. So that is going according to plan. And we're also collaborating with our respective contract manufacturers to address certain observations and deficiencies identified by the FDA in the pre-approval inspections that occurred as part of the original procedure. And it's a six-month review process for a resubmitted BLA. Hence, we are expecting to have a new, so-called data decision date in Q2 next year, and we then hope for an approval and that we can subsequently move towards supporting our US partner, Biogen Inc., for the launch of the product in the US. Um, we're also working together with Strada on prefilled syringes. Um, for the regulatory process in Europe. And we hope that we can get an approval for the prefilled syringe and that it can be launched during the course of next year. And moving on to XB003, our biosimilar candidate to Cimzia. Um, here, as you might recall, we regained the full rights to this program from Bayer at the beginning of August this year. Um, and we have since then been running an active out-licensing process trying to identify a new suitable commercialization partner. Um, and that is moving along, um, and supported by an advisory firm specialized in these kinds of processes, and we have received the first non-binding proposals for such arrangements. Due diligence is ongoing by several different potential counterparties. And we are optimistic in being able to finalize this process and identify a suitable new commercialization partner for this program. Um, I think we also have made quite significant progress in the development. We have successfully scaled up the production process on the drug substance side, which we were very happy with. And we've confirmed analytical similarity versus the reference product at scale. So, the product is getting ready for the clinical phase, and we are planning to have scientific advice meetings with both EMA and FDA in the near future to discuss and align on a suitable clinical development plan for this program. And then we come to Xdivane, our biosimilar candidate to Opdivo. Here, we have also successfully scaled up the drug substance process and confirmed analytical similarity versus the reference product at what is going to be the clinical and commercial scale on the drug substance side. So we're very pleased with that. We have also had interactions with both the EMA and FDA, and we have reached alignment and acceptance on a clinical development plan, which is streamlined compared to the guidelines for biosimilar development, and we are planning a single pivotal trial. And in that streamlined approach, we were able to significantly reduce the envisioned development budget or clinical budget, which we're very happy with and significantly improves the prospects when it comes to identifying and securing a suitable commercialization partner for this program. And in that process, we are also making quite some progress. We have entered into the agreement negotiation phase, and we are hopeful that in the near term future, we will be able to finalize an agreement with a commercialization partner for this program. This will allow us to initiate the clinical trial during the course of the next year together with a future partner. And so that's a brief update where we're at from an operational perspective. So with that said, I'm probably going to hand over to Anette to go through the highlights on the financials.

Anette Lindqvist
12:02 - 17:52

So, thank you, Martin. Um, so my name is Anette Lindqvist. I'm the CFO of Xbrane, and I have the pleasure to take you through some of the financials for the quarter. If we start to look at the net revenues and just as a bit of repetition, let me take a few seconds to take you through the diagram, which can look a bit complicated at first glance. So the first thing is to notice that the bars represent revenue streams by quarter, and the line represents the gross margin. The bars fluctuate quite a bit as revenues are, will, and do fluctuate for various reasons. And that's driven by, well, two major things. The first one is product. Product deliveries to startups, which happen occasionally and on a larger scale. That said, that sale is with little or no margin. Second, there are contractual payments, which can be milestones or other types of contractual payments, all of which come with varying gross margins. So this quarter, we have a total revenue of 67 million with a gross margin of 45%. Last year for Q3, we similarly had 59 million with a gross margin of 40. And on this occasion, that is explained entirely by the fact that last year we had product deliveries to startups. In fact, we haven't had any product deliveries to start this year as we have quite a considerable inventory as well. With Stata, the net profit share for Ximluci was 16 million, as Martin said, somewhat lower than in Q3, Q2, primarily driven by a one-time marketing cost and a slightly lower price mix than we experienced in Q2. We have a milestone attributable to the license agreement with Biogen. And for the gross margin, we have some cancellation fees with our CMOs, related to Ximluci, and also some negative product deviations. Looking at the expenses, the overall expense in the quarter, compared to Q2 and Q4, decreased by 34%. And that is driven mainly by Xdivane. We received positive feedback from the EMA regarding a reduced clinical program. The program met all the capitalization criteria. So hence, from July onwards, we are capitalizing the majority of the cost for Xdivane. And that impacts P&L in the quarter with 12 million. The overall cost savings scheme, in addition to very conscious cost management, with OpEx being held to a minimum, prioritizes program spending; however, all other OpEx is really kept to a minimum. Majority of the R&D spend in the quarter relates to a successful engineering run with our CMO for XB003. XB003. I also would like to repeat that the cost saving scheme was launched in November last year. We have now realized 22 million in savings and we have staff reductions of 35, around 40 as communicated by the program, and we are well on track to deliver the 50 million annually in generated savings. The cash position. I'll take you through some of the major cash flow implications. At the end of June, we had 73 million. The first, the first waterfall milestone is prepayments and net profit generated from Stardust, which gave us 56 million in the quarter. We have Ximluci® production costs of 37 million. The majority consists of cancellation fees, production costs, and also some fees related to Xdivane—sorry, production costs. We have Xdivane development expenses. The 12 million, as I was referring to, was then capitalized later for XB003 upscaling activities and IX look development. And that's where the activity should be. So, around about 12 million in organizational costs like salaries, office consultants, etc. It's 23 million. And then other, including Israeli interest, patents, and everything else. So, we leave the quarter with a cash position of 31 million. And hence, again, we leave with a cash position of 31 million. And the operating cash flow is 15 million. And obviously, that is then impacted by the capitalization activities and also agreed deferral payment plans with our major CMOs. And by that, I turn the word over to Martin.

Unknown 1
17:53 - 17:54

Yeah.

Martin Åmark
17:54 - 20:04

So the key takeaways from the quarter include revenues of 67 million Swedish crowns, coming from Ximluci, profit sharing, and milestones from Biogen. Um, and as we said, we're happy to see the continued growth from a volume perspective on Ximluci® across Europe. We are progressing on the out-licensing efforts for both XB003 and Xdivane, and we are optimistic about being able to, perhaps, secure commercialization partners for both programs and reach a finalized agreement with Xdivane in the near-term future. Um, so that's sort of the highlights and also ties together with the priorities going forward as well. Very well aware, and consistent with our recent communication via press releases, we are very much focused now on finalizing the out-licensing deals on both Xdivane and XB003, to resubmit the BLA for Ximluci or Lucamzi, which is going to be the US brand name, in the fourth quarter to the FDA. Um, and then going into next year, together with partners, we will advance Xdivane and XB003 towards the clinic and support staff in the continued sales uptake for Ximluci in Europe and the introduction of the previous prefilled syringe. And then, of course, also support both Stardust and Valorum in launches. In addition, numerous countries, and of course the US, are dependent on an FDA approval. So those are the priorities going forward here. And with that, I think we probably conclude the presentation and open up for potential questions. And we can start with questions via audio.

Operator
20:07 - 20:32

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Philip Einarsson from Redeye. Please go ahead.

Unknown 2
20:34 - 20:54

Hello, everybody. I’m curious, are there significant quarterly volatilities related to Stardust? Ximluci-related costs, given that the profit split in Q3 is lower than in Q2, despite the growth of 20% and even more in volume?

Martin Åmark
20:56 - 21:32

I would say that historically, there hasn't been significant volatility, but rather a consistent trend towards a stable level from a percentage perspective. But we experienced some one-time marketing costs in this quarter, which we do not expect to see in the coming quarter. But we cannot rule out, of course, that such efforts will have to be done in the future as well. But it was a one-time effect this quarter.

Unknown 2
21:35 - 21:50

Right. Thank you. So the next one relates to the Xdivane out-licensing. And as you mentioned, you're in the negotiation stage. Can you provide any guidance on the parts of the deal that are currently being negotiated?

Martin Åmark
21:53 - 23:00

Um, so this is Xdivane. And the purpose here is to find a commercialization partner to whom we are then granting an exclusive license to the whole program for commercialization in a certain region, if you will. We are having different dialogues, some of which are on a global basis. Other discussions are about one of the two major territories, considering market potential, which are Europe or the US. Um, so that's the nature of the arrangement. And as we have been quite explicit about previously, we're seeking a partner who can bear a significant portion of the upcoming development spend, including particularly the upcoming clinical trial. And, of course, who we believe can successfully commercialize the product.

Unknown 2
23:02 - 23:10

Got it. And I understand from your answer that there is more than one interested party at this point.

Martin Åmark
23:11 - 23:20

Yes. It's still more than one party that is in the process. Indeed, yes.

Unknown 2
23:23 - 23:39

And the last one on this deal then, given the circumstances and the press releases you have sent out recently, how certain are you that you are going to be able to secure a deal with Xdivane? And what happens if you don't? Any comments on that?

Unknown 1
23:40 - 23:41

Um, and.

Martin Åmark
23:41 - 24:40

I mean, we're optimistic given the stage we're at. Yes, the alignment on timelines with respect to counterparties, if you will. Um, so we're optimistic. But of course, we are also, as we've always been, in close dialogue with the existing shareholders as well as potential new investors, both on the debt and equity side. And, we're having continuous dialogues, and we would be hopeful that if we were to meet the dictated timeline, we could find a solution in those discussions to further extend the deadline until finalizing such an agreement.

Unknown 3
24:42 - 24:43

Correct.

Unknown 2
24:44 - 24:54

And the last one for me. Um, how should we view the R&D cost base in the coming, let's say, two quarters, given the ongoing activities?

Unknown 1
24:56 - 24:57

Yeah.

Martin Åmark
24:58 - 26:56

I mean, we do still have quite significant commitments and undertakings on the first three programs. I mean, Ximluci, when it comes to the BLA and the FDA approval as well as the prefilled syringe, we have a quite significant development undertaking there. Furthermore, on Xdivane and XB003, we also have commitments regarding finalizing all preparations for advancing to clinical trials, which include finalizing the production of clinical materials and preparing all documentation necessary for clinical trial applications. So we still have quite significant undertakings and commitments from a development perspective on all these three programs. Um, which makes me believe that R&D spend is going to go up from quarter to quarter. But overall, it should look quite similar to the way it has been seen in the last quarters. I think it's first when we come into Q2 next year and onwards, where we are coming out from these undertakings and in a more significant way are going to be able to reduce the R&D spend. And then, of course, dependent on where we are from a financial perspective and what resources we have, we can consider the initiation of new programs or, let's say, the acceleration of the fourth program in our portfolio, the Darzalex biosimilar candidate. And then, of course, we can. Those decisions will also determine the R&D spend from that point onwards.

Unknown 3
26:58 - 26:59

All right. That's all.

Unknown 2
26:59 - 27:01

For me. Thanks a lot.

Operator
27:08 - 27:16

There are no more questions at this time, so I hand the conference back to the speakers for any written questions and closing comments.

Anette Lindqvist
27:18 - 27:52

Okay. Thank you. Speaker. So the first question coming in from Magnus Tilburg concerns the backup plan in case an agreement is delayed from November and pushed out to December or later. I think that you just responded to that, Martin. So we will go to Magnus Hellström. So what's the reasonable upfront payment for Xdivane™ and for XB003 if the deals are completed? Can investors hope for more than 10 million US dollars upfront for the products combined?

Martin Åmark
27:56 - 28:32

Yes, I think that's a reasonable aspiration. I can remind you that when we out-licensed Ximluci to the startup, we had an upfront of €8 million. And when we outlicensed the XP XB003 to Biogen, we had an 8 million US dollar upfront. So that gives an indication of, let's say, normal and previously seen upfront payments in licensed deals like this.

Anette Lindqvist
28:34 - 28:41

Next question comes from Joachim. How long is the expected approval time for the PFS after EMA has received the application?

Unknown 1
28:43 - 28:44

Um.

Martin Åmark
28:44 - 28:55

Yes. A little bit dependent on the amount and nature of questions received, but I think the time frame is between four to six months.

Anette Lindqvist
28:57 - 29:14

Okay. So next question from Joachim. Again, any possibility to provide any insight on the planned phase three studies? Which indications or labeling are you planning to study in clinic for Xdivane and XB003?

Unknown 1
29:16 - 29:17

Um.

Martin Åmark
29:17 - 31:11

Yes. I mean, Xdivane. We have a planned study design for the upcoming trial, and the most likely indication is melanoma. Melanoma is the main indication of the reference product and the one which we believe is most feasible from the perspective of being able to recruit patients within the shortest possible time. Additionally, we can conduct this trial in a monotherapy setting, which greatly simplifies particularly measuring pharmacokinetics, a key aspect of this upcoming trial. When it comes to Cimzia or XB003, we are currently in the phase of designing the clinical trial, and we're planning to interact with the regulatory authorities in the first quarter of next year. Um, and I guess the ambition is to do a phase one. And I guess the ambition is that this could also be the single pivotal trial. And to do that in healthy volunteers, because that's possible for that product. If not, and if a study in patients is required, it will probably be conducted with a psoriasis indication. But we haven't fully decided yet as we are still going through the process.

Unknown 4
31:12 - 31:12

Um, the.

Martin Åmark
31:12 - 31:23

Design of those respective planned studies and are also having the scientific advisors with EMA and FDA pending.

Anette Lindqvist
31:26 - 31:47

Uh, okay. Then, it's about the attractiveness for Xdivane regarding EMA and FDA's positive feedback on the streamlined clinical development plans. How do you feel this will help in securing a larger upfront payment from the non-binding proposals that we already received versus the agreement now on the table?

Unknown 1
31:49 - 31:50

Um.

Martin Åmark
31:51 - 32:45

And I think it will reflect a smaller investment needed. On the potential partner side, I think this will reflect a higher profit-sharing on behalf of Xbrane Biopharma than would otherwise be the case. If two separate phases, phase one and phase three trials, had to be conducted, the budget would have been more than double compared to what we are currently looking at. So I think it's more that aspect that is going to be impacted, rather than the upfront itself. And we discussed in a previous question what has previously been seen and what reasonably can be expected when it comes to upfront payments for this specific program.

Anette Lindqvist
32:46 - 33:01

Okay. So then, the next question from Magnus Tilbe: in case the share is significantly higher than 0.29 at the end of the year, how do you plan to manage that?

Martin Åmark
33:03 - 34:03

I think this question is probably related to the outstanding series of warrants which have a strike price of 0.29 Swedish crowns. So, if those warrants were not in the money, that would mean they would most likely not be exercised, resulting in a shortfall in cash influx into the company, which would otherwise occur if the share price were above 0.29 or 29 Swedish crowns and the warrants were in the money, consequently being most likely exercised. So I guess this is the consequence. But that is just one. Um, one other uncertainty when it comes to upcoming cash flow, um, in combination with a few others, let's say. So, that is, I guess, the way we're handling it. Yeah.

Anette Lindqvist
34:07 - 34:15

Oh, okay. I don't see any more questions. So, operator, is there anything more from the audio?

Operator
34:18 - 34:24

There are no more questions on the teleconference. You can proceed with your final greetings.

Unknown 1
34:26 - 34:27

Okay.

Martin Åmark
34:27 - 35:06

And then we thank all of you who participated in the call. And as always, we are here. Um, should you have any further questions? We're available over email or phone, and we hope to be able to communicate back to all of you in the near term future with hopefully being able to be successful in our endeavors and finalize license agreements with both Xdivane and XB003, and then follow on with our other ambitions for the upcoming year. Thank you.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…